Sibra 15 mg Elbrus Pharmaceuticals

Description

Sibra 15 mg Elbrus Pharmaceuticals — Manufactured to exacting pharmaceutical standards, this pharmaceutical-grade thermogenic compound accelerates fat metabolism and supports lean body composition during cutting phases. Enhances metabolic rate while preserving lean muscle tissue. This formulation is dosed at 15 mg per unit.

Key Benefits

• Serotonin-norepinephrine reuptake inhibitor — centrally-acting appetite suppressor
• Metabolic rate elevation modest; mechanism primarily satiety
• Withdrawn from many markets due to cardiovascular signal
• Oral daily dosing during cutting
• Not first-line in modern weight-loss protocols (GLP-1 agonists preferred)
• Each unit dosed at 15 mg — see Recommended Dosage below for protocol-specific intake

How It Works

Central serotonin and norepinephrine reuptake inhibitor (SNRI). Increases satiety signals and modestly raises basal metabolic rate. Withdrawn from EU, US, and most developed markets in 2010 after cardiovascular-event signal in SCOUT trial.

Pharmacokinetics

Plasma half-life approximately 14–16 hours (active metabolites longer). Daily morning dosing. Steady-state 4–5 days.

Potential Side Effects

Blood-pressure elevation, tachycardia, dry mouth, insomnia. Cardiovascular events in susceptible individuals — primary reason for market withdrawal. Not for hypertensive or CVD patients.

Cycle & Stacking Guide

8–12 week cutting protocols with weekly BP monitoring. Modern alternative: semaglutide or tirzepatide with far cleaner safety profile.

Manufacturer Notes

Elbrus Pharmaceuticals is an Eastern European producer with GMP certification. Their pharmacology catalogue is broad, covering AAS, peptides, and harm-reduction supports.

Storage & Handling

Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.